BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 34003775)

  • 1. The Transcriptomic Landscape of Mismatch Repair-Deficient Intestinal Stem Cells.
    Bommi PV; Bowen CM; Reyes-Uribe L; Wu W; Katayama H; Rocha P; Parra ER; Francisco-Cruz A; Ozcan Z; Tosti E; Willis JA; Wu H; Taggart MW; Burks JK; Lynch PM; Edelmann W; Scheet PA; Wistuba II; Sinha KM; Hanash SM; Vilar E
    Cancer Res; 2021 May; 81(10):2760-2773. PubMed ID: 34003775
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Temozolomide increases the number of mismatch repair-deficient intestinal crypts and accelerates tumorigenesis in a mouse model of Lynch syndrome.
    Wojciechowicz K; Cantelli E; Van Gerwen B; Plug M; Van Der Wal A; Delzenne-Goette E; Song JY; De Vries S; Dekker M; Te Riele H
    Gastroenterology; 2014 Nov; 147(5):1064-72.e5. PubMed ID: 25088490
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An Msh2 conditional knockout mouse for studying intestinal cancer and testing anticancer agents.
    Kucherlapati MH; Lee K; Nguyen AA; Clark AB; Hou H; Rosulek A; Li H; Yang K; Fan K; Lipkin M; Bronson RT; Jelicks L; Kunkel TA; Kucherlapati R; Edelmann W
    Gastroenterology; 2010 Mar; 138(3):993-1002.e1. PubMed ID: 19931261
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevalence of mismatch repair-deficient crypt foci in Lynch syndrome: a pathological study.
    Kloor M; Huth C; Voigt AY; Benner A; Schirmacher P; von Knebel Doeberitz M; Bläker H
    Lancet Oncol; 2012 Jun; 13(6):598-606. PubMed ID: 22552011
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Teenage-Onset Colorectal Cancers in a Digenic Cancer Predisposition Syndrome Provide Clues for the Interaction between Mismatch Repair and Polymerase δ Proofreading Deficiency in Tumorigenesis.
    Schamschula E; Kinzel M; Wernstedt A; Oberhuber K; Gottschling H; Schnaiter S; Friedrichs N; Merkelbach-Bruse S; Zschocke J; Gallon R; Wimmer K
    Biomolecules; 2022 Sep; 12(10):. PubMed ID: 36291559
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Small Bowel Adenocarcinoma Frequently Exhibits Lynch Syndrome-associated Mismatch Repair Protein Deficiency But Does Not Harbor Sporadic MLH1 Deficiency.
    Xia M; Singhi AD; Dudley B; Brand R; Nikiforova M; Pai RK
    Appl Immunohistochem Mol Morphol; 2017 Jul; 25(6):399-406. PubMed ID: 27258561
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mesalazine and thymoquinone attenuate intestinal tumour development in Msh2(loxP/loxP) Villin-Cre mice.
    Kortüm B; Campregher C; Lang M; Khare V; Pinter M; Evstatiev R; Schmid G; Mittlböck M; Scharl T; Kucherlapati MH; Edelmann W; Gasche C
    Gut; 2015 Dec; 64(12):1905-12. PubMed ID: 25429050
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Crypt residing bacteria and proximal colonic carcinogenesis in a mouse model of Lynch syndrome.
    Lang M; Baumgartner M; Rożalska A; Frick A; Riva A; Jarek M; Berry D; Gasche C
    Int J Cancer; 2020 Oct; 147(8):2316-2326. PubMed ID: 32350866
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mismatch Repair Deficiency in Ovarian Carcinoma: Frequency, Causes, and Consequences.
    Leskela S; Romero I; Cristobal E; Pérez-Mies B; Rosa-Rosa JM; Gutierrez-Pecharroman A; Caniego-Casas T; Santón A; Ojeda B; López-Reig R; Palacios-Berraquero ML; García Á; Ibarra J; Hakim S; Guarch R; López-Guerrero JA; Poveda A; Palacios J
    Am J Surg Pathol; 2020 May; 44(5):649-656. PubMed ID: 32294063
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MET Signaling Mediates Intestinal Crypt-Villus Development, Regeneration, and Adenoma Formation and Is Promoted by Stem Cell CD44 Isoforms.
    Joosten SPJ; Zeilstra J; van Andel H; Mijnals RC; Zaunbrecher J; Duivenvoorden AAM; van de Wetering M; Clevers H; Spaargaren M; Pals ST
    Gastroenterology; 2017 Oct; 153(4):1040-1053.e4. PubMed ID: 28716720
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune Profiling of Premalignant Lesions in Patients With Lynch Syndrome.
    Chang K; Taggart MW; Reyes-Uribe L; Borras E; Riquelme E; Barnett RM; Leoni G; San Lucas FA; Catanese MT; Mori F; Diodoro MG; You YN; Hawk ET; Roszik J; Scheet P; Kopetz S; Nicosia A; Scarselli E; Lynch PM; McAllister F; Vilar E
    JAMA Oncol; 2018 Aug; 4(8):1085-1092. PubMed ID: 29710228
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sporadic and Lynch syndrome-associated mismatch repair-deficient brain tumors.
    Kim H; Lim KY; Park JW; Kang J; Won JK; Lee K; Shim Y; Park CK; Kim SK; Choi SH; Kim TM; Yun H; Park SH
    Lab Invest; 2022 Feb; 102(2):160-171. PubMed ID: 34848827
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Universal Immunohistochemistry for Lynch Syndrome: A Systematic Review and Meta-analysis of 58,580 Colorectal Carcinomas.
    Eikenboom EL; van der Werf-'t Lam AS; Rodríguez-Girondo M; Van Asperen CJ; Dinjens WNM; Hofstra RMW; Van Leerdam ME; Morreau H; Spaander MCW; Wagner A; Nielsen M
    Clin Gastroenterol Hepatol; 2022 Mar; 20(3):e496-e507. PubMed ID: 33887476
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular analysis of Iranian colorectal cancer patients at risk for Lynch syndrome: a new molecular, clinicopathological feature.
    Zeinalian M; Emami MH; Salehi R; Naimi A; Kazemi M; Hashemzadeh-Chaleshtori M
    J Gastrointest Cancer; 2015 Jun; 46(2):118-25. PubMed ID: 25722176
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acetaldehyde and defective mismatch repair increase colonic tumours in a Lynch syndrome model with Aldh1b1 inactivation.
    Cerretelli G; Zhou Y; Müller MF; Adams DJ; Arends MJ
    Dis Model Mech; 2023 Aug; 16(8):. PubMed ID: 37395714
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Functional analysis of MSH2 unclassified variants found in suspected Lynch syndrome patients reveals pathogenicity due to attenuated mismatch repair.
    Wielders EA; Hettinger J; Dekker R; Kets CM; Ligtenberg MJ; Mensenkamp AR; van den Ouweland AM; Prins J; Wagner A; Dinjens WN; Dubbink HJ; van Hest LP; Menko F; Hogervorst F; Verhoef S; te Riele H
    J Med Genet; 2014 Apr; 51(4):245-53. PubMed ID: 24501230
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Distinct gene expression signatures in lynch syndrome and familial colorectal cancer type x.
    Dominguez-Valentin M; Therkildsen C; Veerla S; Jönsson M; Bernstein I; Borg A; Nilbert M
    PLoS One; 2013; 8(8):e71755. PubMed ID: 23951239
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Three molecular pathways model colorectal carcinogenesis in Lynch syndrome.
    Ahadova A; Gallon R; Gebert J; Ballhausen A; Endris V; Kirchner M; Stenzinger A; Burn J; von Knebel Doeberitz M; Bläker H; Kloor M
    Int J Cancer; 2018 Jul; 143(1):139-150. PubMed ID: 29424427
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mouse models for hereditary nonpolyposis colorectal cancer.
    de Wind N; Dekker M; van Rossum A; van der Valk M; te Riele H
    Cancer Res; 1998 Jan; 58(2):248-55. PubMed ID: 9443401
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Germline mutation analysis of MLH1 and MSH2 in Malaysian Lynch syndrome patients.
    Zahary MN; Kaur G; Abu Hassan MR; Singh H; Naik VR; Ankathil R
    World J Gastroenterol; 2012 Feb; 18(8):814-20. PubMed ID: 22371642
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.